immunitoAI is a TechBio company Unleashing the Full Potential of Antibody Therapeutics.  Our AI Platform AbInitio™ Is How We Get There.

Our vision is to unleash the full potential of antibody-based biological drugs and make antibody therapy the norm.

To get there, our AI platform, AbInitio™, generates novel antibody therapeutics with predefined drug characteristics for any protein target — validated through in-house biological methods.

Biology First

• Your target. Or ours.

• Biologics Team locks the epitope first

• Mechanism of action defined before design begins

• Disease biology sets the target

• Disease biology sets the epitope

• Disease biology defines what the antibody must do on binding

Drug First

• Designed to a drug profile — not just a binder

• First-in-class where none exists

• Best-in-class where one does

• Format follows biology: monovalent, multivalent, multi-specific

• Engineered to the target's exact potency and safety window